Lv42
710 积分 2024-06-27 加入
Esophageal cancer: emerging therapeutics
11小时前
待确认
Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial
12小时前
已完结
Profile of treatment-related adverse events of PD-1 blockade-based therapies in advanced esophageal cancer: A systematic review and meta-analysis
1天前
已完结
Comprehensive molecular characterization of esophageal carcinoma
1天前
已关闭
An innovative antibody fusion protein targeting PD-L1, VEGF and TGF-β with enhanced antitumor efficacies
7天前
已完结
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study
7天前
已完结
Targeting Esophageal Cancer: Promising Drugs for the Clinical Landscape and Key Knowledge Gaps
8天前
已完结
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
9天前
已完结
1545P CS2009, a novel PD-1/VEGF/CTLA-4 trispecific antibody, in patients with advanced solid tumors: An open-label, multicenter, phase I first-in-human study
9天前
已关闭
Esophageal cancer: emerging therapeutics
9天前
已完结
皖公网安备34019202002308
